Anaptysbio (ANAB) Cash from Investing Activities Growth (3y) (2019 - 2026)

Anaptysbio (ANAB) Cash from Investing Activities Growth (3y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -29.84%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 38.24%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -22.09%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Anaptysbio 1.55 Bn 1.27 Bn - -25.73%

Historic Data

Download Data
DateValue
Mar 31, 2026 -25.73%
Dec 31, 2025 50.65%
Sep 30, 2025 73.07%
Jun 30, 2025 35.95%
Mar 31, 2025 26.98%
Dec 31, 2024 23.90%
Sep 30, 2024 75.53%
Jun 30, 2024 -27.33%
Mar 31, 2024 6.55%
Dec 31, 2023 139.09%
Sep 30, 2023 86.38%
Jun 30, 2023 -31.45%
Mar 31, 2023 99.52%
Dec 31, 2022 74.65%
Sep 30, 2022 -36.47%
Jun 30, 2022 -47.77%
Mar 31, 2022 -225.23%
Dec 31, 2021 26.23%
Sep 30, 2021 -23.92%
Jun 30, 2021 143.27%